Table 2. Final Covariates in Multivariable Model and Associated Point Values for CR Pseudomonas aeruginosa Infectiona.
| Variable | OR (95% CI) | P Value | Pointsb |
|---|---|---|---|
| Intercept | NA | NA | NA |
| SNF transfer | 1.36 (1.08-1.72) | .009 | 1 |
| Tracheostomy (from admission to culture date) | 3.49 (2.92-4.16) | <.001 | 4 |
| P aeruginosa infection 30 d before index admission | |||
| None | 1 [Reference] | <.001 | NA |
| Carbapenem-susceptible | 0.58 (0.47-0.71) | −2 | |
| CR | 8.80 (6.74-11.49) | 7 | |
| Previous hospitalization 6 mo before index admission | 1.80 (1.51-2.15) | <.001 | 2 |
| Carbapenems 30 d before the index date | 4.18 (3.29-5.31) | <.001 | 5 |
| Other cephalosporins 30 d before the index datec | 0.77 (0.66-0.91) | .002 | −1 |
| Quinolones | 1.53 (1.29-1.81) | <.001 | 1 |
Abbreviations: CR, carbapenem resistant; NA, not applicable; OR, odds ratio; SNF, skilled nursing facility.
a
Includes 5834 patients.
b
Calculated as weighted sums of regression coefficients from the prediction model; patient’s risk was estimated as the inverse logit of the risk score. Scores range from −3 to 20; higher risk scores are associated with greater predicted risk of resistant infection. Constant for the point system, Β = 0.3109.
c
Includes cefaclor, cefazolin sodium, cefixime, cefotaxime sodium, cefotetan disodium, cefoxitin sodium, cefpodoxime proxetil, ceftriaxone sodium, cefuroxime sodium, and cephalexin and excludes ceftazidime, cefepime hydrochloride, and a combination of ceftolozane sulfate and tazobactam sodium.